About ExcaliVir

Transforming Pathogen Detection

ExcaliVir is a molecular diagnostics company that is transforming pathogen detection by combining next generation microarray and sequencing. The company’s primary focus is the diagnosis and management of cancer.

ExcaliVir’s proprietary technology, PathoChip, is the most extensive microarray platform available for pathogen detection, providing fast, accurate detection of pathogens that may cause or complicate a disease, impacting treatment, prognosis, and follow-up. Using the Pathochip as a discovery engine, we are identifying specific microbial signatures associated with cancer, providing biomarkers to enhance diagnostic screening, assessment of the aggressiveness of the cancer, selection of targeted therapies, and monitoring for recurrence.


ExcaliVir was formed in 2012 by Dr. Erle Robertson and Dr. James Alwine, investigators at the University of Pennsylvania, Perelman School of Medicine. Their passion for research on the relationship between the microbiome and human cancer was realized through a $1.4 million grant from the Avon Foundation, $50,000 from Agilent Inc, and a generous gift from the Abramson Cancer Center of the University of Pennsylvania. With this support, Drs. Robertson and Alwine were able to develop a unique technology for rapid identification of all known known viruses and all known human pathogenic bacteria, parasites and fungi.